zenocutuzumab   Click here for help

GtoPdb Ligand ID: 13649

Synonyms: Bizengri® | MCLA-128 | PB4188 [3] | R040517 | zenocutuzumab-zbco
Approved drug
zenocutuzumab is an approved drug (FDA (2024))
Compound class: Antibody
Comment: Zenocutuzumab (MCLA-128) is a humanized IgG1 bispecific anti-epidermal growth factor receptor 2/3 (HER2/HER3) monoclonal antibody [2-3]. It prevents binding of the ligand neuregulin 1 (NRG1) to HER3 and this suppresses HER2/HER3 dimerization, phosphorylation and downstream signalling [8]. Genetic NRG1 fusions have been identified as oncogenic drivers in a small number of tumour types [4,6]. Zenocutuzumab-mediated modulation inhibits signalling through the PI3K-AKT-mTOR pathway and reduces tumour cell growth and invasiveness. Low fucose glycoengineering enhances zenocutuzumab's antibody-dependent cellular cytotoxicity (ADCC) activity.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2024)
International Nonproprietary Names Click here for help
INN number INN
10687 zenocutuzumab
Synonyms Click here for help
Bizengri® | MCLA-128 | PB4188 [3] | R040517 | zenocutuzumab-zbco
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 771
Other databases
GtoPdb PubChem SID 507750283
Search PubMed clinical trials zenocutuzumab
Search PubMed titles zenocutuzumab
Search PubMed titles/abstracts zenocutuzumab